647 related articles for article (PubMed ID: 8639453)
1. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden.
Rintelen C; Mannhalter C; Ireland H; Lane DA; Knöbl P; Lechner K; Pabinger I
Br J Haematol; 1996 May; 93(2):487-90. PubMed ID: 8639453
[TBL] [Abstract][Full Text] [Related]
2. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
[TBL] [Abstract][Full Text] [Related]
3. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
4. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
[TBL] [Abstract][Full Text] [Related]
5. Factor V Leiden: should we screen oral contraceptive users and pregnant women?
Vandenbroucke JP; van der Meer FJ; Helmerhorst FM; Rosendaal FR
BMJ; 1996 Nov; 313(7065):1127-30. PubMed ID: 8916702
[TBL] [Abstract][Full Text] [Related]
6. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism.
Bennet L; Odeberg H
J Intern Med; 1998 Jul; 244(1):27-32. PubMed ID: 9698021
[TBL] [Abstract][Full Text] [Related]
7. Effects of oral contraceptives on hemostasis and thrombosis.
Rosing J; Tans G
Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S375-82. PubMed ID: 10368524
[TBL] [Abstract][Full Text] [Related]
8. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
Price DT; Ridker PM
Ann Intern Med; 1997 Nov; 127(10):895-903. PubMed ID: 9382368
[TBL] [Abstract][Full Text] [Related]
9. Oral contraception and factor V Leiden mutation in relation to localization of deep vein thrombosis.
Andersen BS; Olsen J
Thromb Res; 1998 May; 90(4):191-4. PubMed ID: 9692618
[TBL] [Abstract][Full Text] [Related]
10. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
Heinemann LA; Assmann A; Spannagl M; Schramm W; Dick A; Kluft C; de Maat MP
Contraception; 1998 Nov; 58(5):321-2. PubMed ID: 9883389
[TBL] [Abstract][Full Text] [Related]
11. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study.
Farmer RD; Todd JC; Lewis MA; MacRae KD; Williams TJ
Contraception; 1998 Feb; 57(2):67-70. PubMed ID: 9589831
[TBL] [Abstract][Full Text] [Related]
12. Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies.
Girolami A; Zanon E; Zanardi S; Saracino MA; Simioni P
Blood Coagul Fibrinolysis; 1996 Jun; 7(4):497-501. PubMed ID: 8840004
[TBL] [Abstract][Full Text] [Related]
13. Resistance to activated protein C in healthy women taking oral contraceptives.
Olivieri O; Friso S; Manzato F; Guella A; Bernardi F; Lunghi B; Girelli D; Azzini M; Brocco G; Russo C
Br J Haematol; 1995 Oct; 91(2):465-70. PubMed ID: 8547095
[TBL] [Abstract][Full Text] [Related]
14. First-time use of newer oral contraceptives and the risk of venous thromboembolism.
Suissa S; Blais L; Spitzer WO; Cusson J; Lewis M; Heinemann L
Contraception; 1997 Sep; 56(3):141-6. PubMed ID: 9347203
[TBL] [Abstract][Full Text] [Related]
15. Thrombotic tendency in 75 symptomatic, unrelated patients with APC resistance.
Melichart M; Kyrle PA; Eichinger S; Rintelen C; Mannhalter C; Pabinger I
Wien Klin Wochenschr; 1996; 108(19):607-10. PubMed ID: 8921576
[TBL] [Abstract][Full Text] [Related]
16. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
[TBL] [Abstract][Full Text] [Related]
17. Smoking and use of oral contraceptives: impact on thrombotic diseases.
Lidegaard O
Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S357-63. PubMed ID: 10368521
[TBL] [Abstract][Full Text] [Related]
18. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.
Rosing J; Tans G; Nicolaes GA; Thomassen MC; van Oerle R; van der Ploeg PM; Heijnen P; Hamulyak K; Hemker HC
Br J Haematol; 1997 Apr; 97(1):233-8. PubMed ID: 9136971
[TBL] [Abstract][Full Text] [Related]
19. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives.
Hellgren M; Svensson PJ; Dahlbäck B
Am J Obstet Gynecol; 1995 Jul; 173(1):210-3. PubMed ID: 7631684
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
